Want to see GB:OBI full AI Analyst Report?
Ondine Biomedical, Inc. (OBI) AI Stock Analysis
Top Page
Ondine Biomedical, Inc.
(LSE:OBI)
The score is primarily held back by very weak financial quality—extreme losses, declining gross margin, and worsening cash burn that elevates financing risk. Technicals also weigh negatively, with the stock trading below major moving averages and weak momentum signals. Valuation is difficult to support due to negative earnings and no indicated dividend yield, resulting in a cautious overall rating.
Ondine Biomedical, Inc. (OBI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 62.82M
- Dividend Yield
- ―
- Average Volume (3M)
- 624.92K
- Price to Earnings (P/E)
- -2.8
- Beta (1Y)
- 0.30
- Revenue Growth
- 26.99%
- EPS Growth
- 4.36%
- Country
- UK
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ondine Biomedical, Inc. Business Overview & Revenue Model
Company Description
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Phot...
How the Company Makes Money
Publicly available, specific details of Ondine Biomedical, Inc.’s (OBI’s) current revenue model, key revenue streams (e.g., product sales, licensing/royalties, services), and material commercial partnerships are null. At a high level, companies comme...
Ondine Biomedical, Inc. Financial Statement Overview
Summary
Revenue growth is strong (2025 up ~18% vs. 2024), but profitability is extremely weak (net margin around -1,116%) and gross margin fell sharply (~64% to ~41%). Cash flow is a major concern with worsening operating cash burn (~-£23.9M in 2025 vs. ~-£15.5M in 2024) and similarly negative free cash flow, increasing funding/financing risk despite modest leverage (debt-to-equity ~0.12).
Income Statement
24NegativeBalance Sheet
56NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.85M | 2.65M | 2.05M | 1.20M | 638.00K | 2.57M |
| Gross Profit | 1.26M | 1.09M | 1.32M | 703.00K | 287.00K | 1.25M |
| EBITDA | -32.52M | -29.45M | -18.49M | -13.79M | -18.85M | -48.36M |
| Net Income | -32.83M | -29.59M | -19.10M | -14.41M | -19.37M | -50.09M |
Balance Sheet | ||||||
| Total Assets | 8.95M | 14.40M | 12.82M | 5.73M | 16.57M | 34.14M |
| Cash, Cash Equivalents and Short-Term Investments | 5.36M | 10.58M | 9.77M | 2.98M | 13.13M | 30.36M |
| Total Debt | 278.87K | 413.50K | 168.00K | 541.00K | 896.00K | 739.00K |
| Total Liabilities | 12.17M | 10.91M | 5.95M | 3.65M | 4.92M | 4.48M |
| Stockholders Equity | -3.22M | 3.49M | 6.88M | 2.08M | 11.64M | 29.66M |
Cash Flow | ||||||
| Free Cash Flow | -26.80M | -24.02M | -15.50M | -13.83M | -16.66M | -12.62M |
| Operating Cash Flow | -26.60M | -23.90M | -15.49M | -13.65M | -16.34M | -12.54M |
| Investing Cash Flow | -203.77K | -117.28K | -10.00K | -177.00K | -311.00K | -77.00K |
| Financing Cash Flow | 26.67M | 24.28M | 21.74M | 3.79M | -275.00K | 41.90M |
Ondine Biomedical, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBI, the sentiment is Negative. The current price of 9.75 is below the 20-day moving average (MA) of 9.80, below the 50-day MA of 10.44, and below the 200-day MA of 11.76, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 41.46 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBI.
Ondine Biomedical, Inc. Peers Comparison
Overall Rating
GB:ONT59Neutral
GB:SBTX59Neutral
GB:4BB52Neutral
GB:POLB46Neutral- GB:OBI44Neutral
GB:AVCT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:ONT | 59Neutral | GBP 2.18B | -17.72 | -27.36% | ― | 14.80% | 16.88% |
| GB:SBTX | 59Neutral | GBP 13.61M | -29.17 | -5.25% | ― | 95.16% | 85.60% |
| GB:4BB | 52Neutral | GBP 82.07M | -4.57 | -316.73% | ― | -56.10% | -16.77% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:POLB | 46Neutral | GBP 49.62M | -8.33 | -71.28% | ― | ― | 31.58% |
| GB:OBI | 44Neutral | GBP 64.47M | -2.83 | -9999.00% | ― | 26.99% | 4.36% |
| GB:AVCT | 43Neutral | GBP 294.51M | -6.63 | -1293.07% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:OBI | Ondine Biomedical, Inc. | 9.75 | -3.00 | -23.53% | |
| GB:AVCT | Avacta Group plc | 60.50 | -11.50 | -15.97% | |
| GB:SBTX | SkinBioTherapeutics plc | 5.25 | -10.88 | -67.44% | |
| GB:4BB | 4basebio UK Societas | 530.00 | -255.00 | -32.48% | |
| GB:POLB | Poolbeg Pharma Ltd. | 6.50 | 2.65 | 68.83% | |
| GB:ONT | Oxford Nanopore Technologies PLC | 222.60 | 87.10 | 64.28% |
Ondine Biomedical, Inc. Corporate Events
Ondine Biomedical’s Phase 3 Trial Shows 40% Cut in Surgical Site Infections
PositiveOndine Biomedical reported strong topline results from its 5,188-patient Phase 3 LANTERN trial evaluating its nasal photodisinfection therapy to prevent surgical site infections across 18 hospitals in the U.S. and Canada. The study met its primary ef...
Ondine Biomedical Launches Steriwave Infection-Prevention Pilot with Mexico’s Hospital Ángeles
PositiveOndine Biomedical has partnered with Mexico’s Hospital Ángeles Health System to pilot its Steriwave nasal photodisinfection therapy in two flagship hospitals, Acoxpa in Mexico City and Valle Oriente in Monterrey. The initiative follows pos...
Ondine’s Phase 3 Trial Shows 40% Cut in Surgical Site Infections
PositiveOndine Biomedical has reported positive topline results from its Phase 3 LANTERN trial, which tested its nasal photodisinfection technology as an add-on to standard care for preventing surgical site infections. The study enrolled 5,188 patients acros...
Ondine’s Steriwave Adopted by Scotland’s Largest Joint Replacement Centre
PositiveNHS Golden Jubilee, the UK’s largest hip and knee replacement centre and a key provider of elective orthopaedic care in Scotland, has become the first hospital in the country to adopt Ondine Biomedical’s Steriwave nasal photodisinfection...
Ondine Biomedical Narrows Timeline for Phase 3 LANTERN Trial Results
PositiveOndine Biomedical has updated the expected timing for topline results from its LANTERN Phase 3 pivotal study of its nasal photodisinfection therapy to cut surgical site infections, with data now anticipated in about six weeks as final data management...
Ondine Showcases Steriwave at Photodynamic Forum as Phase 3 Trial Advances
PositiveOndine Biomedical, a developer of non-antibiotic, light-activated antimicrobial therapies, is building a portfolio around its Steriwave nasal photodisinfection platform and related photodisinfection products for a range of infection-related indicatio...
Ondine Biomedical shareholders back board and auditors at AGM
PositiveShareholders of Ondine Biomedical Inc. unanimously backed the re-election of chair Carolyn Cross and president Nicolas G. Loebel at the company’s 30 June Annual General Meeting, with all other director nominees also securing strong support desp...
Ondine’s Steriwave Cuts Skull-Base Surgery Infections by 78% in Leeds Study
PositiveOndine Biomedical reported that a study from Leeds Teaching Hospitals has been published showing its Steriwave nasal photodisinfection system significantly outperforms standard mupirocin-based care in endoscopic anterior skull-base surgery. The singl...
Ondine Nears Top-Line Data from Landmark Phase 3 Study of Nasal Photodisinfection
PositiveOndine Biomedical has announced progress in its LANTERN Phase 3 pivotal trial evaluating its non-antibiotic nasal photodisinfection technology for reducing surgical site infections. Endpoint adjudication is complete, principal investigators are final...
Ondine’s nasal photodisinfection cuts infections in complex brain surgery
PositiveOndine Biomedical reported interim results from a 189-patient study at Leeds Teaching Hospitals showing that its Steriwave nasal photodisinfection, applied immediately before complex brain surgery performed through the nose, reduced surgical site inf...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 12, 2026